EFG International AG Acquires Shares of 62,029 Halozyme Therapeutics, Inc. $HALO

EFG International AG bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 62,029 shares of the biopharmaceutical company’s stock, valued at approximately $4,855,000.

Other hedge funds have also recently made changes to their positions in the company. Canada Pension Plan Investment Board bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $10,379,000. Legal & General Group Plc purchased a new position in Halozyme Therapeutics in the second quarter worth about $25,288,000. The Manufacturers Life Insurance Company bought a new stake in Halozyme Therapeutics during the second quarter worth approximately $13,624,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in Halozyme Therapeutics during the second quarter worth approximately $117,000. Finally, Cetera Trust Company N.A purchased a new stake in Halozyme Therapeutics during the second quarter valued at approximately $489,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 0.6%

Shares of NASDAQ HALO opened at $109.32 on Wednesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $109.55. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market cap of $12.41 billion, a price-to-earnings ratio of 32.63, a PEG ratio of 0.44 and a beta of 0.85. The business’s 50 day moving average price is $84.73 and its 200-day moving average price is $74.19.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HALO has been the subject of several analyst reports. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. UBS Group restated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Weiss Ratings downgraded Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, August 14th. Finally, Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.